Zicam maker fights criticism

Allegations that Matrixx Initiatives' Zicam nasal spray causes loss of sense of smell in some users are being called a "financial play," by company officials who say one critic's son is short-selling their stock. The company said none of their clinical trials have shown a loss of smell related to Zicam, which is used to treat cold symptoms. The U.S. Food and Drug Administration confirmed it is following up on consumer complaints, but refused to say whether it will launch a formal investigation.

View Full Article in:

Arizona Republic (Phoenix) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC